Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients

Acta Pharmacologica Sinica

Volumn 29, Issue 8, 2008, Pages 983-989

  He, Ya Yi ^a   Zhang, Rong ^a   Shao, Xin Yu ^a   Hu, Cheng ^a   Wang, Cong Rong ^a   Lu, Jun Xi ^a   Bao, Yu Qian ^a   Jia, Wei Ping ^a   Xiang, Kun San ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Pharmaco genomics; Polymorphism; Repaglinide; Type 2 diabetes

Indexed keywords

ARGININE; GLUCOSE; HEMOGLOBIN A1C; REPAGLINIDE;

ADULT; AGED; ARTICLE; CELL FUNCTION; DRUG RESPONSE; EXON; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PROVOCATION TEST; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT DURATION;

ATP-BINDING CASSETTE TRANSPORTERS; CARBAMATES; DIABETES MELLITUS, TYPE 2; DNA; FEMALE; GENE FREQUENCY; GENOTYPE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PIPERIDINES; POLYMORPHISM, GENETIC; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG;

EID: 49249118751     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00840.x     Document Type: Article

References (31)

1. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002 41 : 471 83.
2. Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab 2006 91 : 2334 9.
3. Grell W, Hurnaus R, Griss G, Sauter R, Rupprecht E, Mark M, et al. Repaglinide and related hypoglycemic benzoic acid derivatives. J Med Chem 1998 41 : 5219 46.
4. Rizzo MR, Barbieri M, Grella R, Passariello N, Barone M, Paolisso G. Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study. Diabetes Metab 2004 30 : 81 9.
5. Owens DR, Luzio SD, Ismail I, Bayer T. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 2000 23 : 518 23.
6. Gromada J, Dissing S, Kofod H, Frokjaer-Jensen J. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia 1995 38 : 1025 32.
7. Hansen AM, Hansen JB, Carr RD, Ashcroft FM, Wahl P. Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels. Br J Pharmacol 2005 144 : 551 7.
8. Dabrowski M, Wahl P, Holmes WE, Ashcroft FM. Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels. Diabetologia 2001 44 : 747 56.
9. Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol 1999 61 : 337 62.
10. Yokoi N, Kanamori M, Horikawa Y, Takeda J, Sanke T, Furuta H, et al. Association studies of variants in the genes involved in pancreatic beta-cell function in type 2 diabetes in Japanese subjects. Diabetes 2006 55 : 2379 86.
11. Laukkanen O, Pihlajamaki J, Lindstrom J, Eriksson J, Valle T, Hamalainen H, et al. Polymorphisms of the SURl (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 2004 89 : 6286 90.
12. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999 16 : 442 3.
13. Larsson H, Ahren B. Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine. Diabetologia 1998 41 : 772 7.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 : 412 9.
15. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999 43 : 155 66.
16. Jovanovic L, Dailey G 3rd., Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000 40 : 49 57.
17. Gerstein HC, Garon J, Joyce C, Rolfe A, Walter CM. Pre-prandial vspost-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial. Diabet Med 2004 21 : 1200 3.
18. Van Gaal LF, Van Acker KL, De Leeuw IH. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes. Diabetes Res Clin Pract 2001 53 : 141 8.
19. Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 2001 24 : 11 5.
20. Li J, Tian H, Li Q, Wang N, Wu T, Liu Y, et al. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes Metab 2007 9 : 558 65.
21. Liu Z, Zhang YW, Feng QP, Li YF, Wu GD, Zuo J, et al. Association analysis of 30 type 2 diabetes candidate genes in Chinese Han population. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2006 28 : 124 8.
22. Ji L, Han X, Wang H. Sulfonylurea receptor gene polymorphism is associated with non-insulin dependent diabetes mellitus in Chinese population. Zhonghua Yi Xue Za Zhi 1998 78 : 774 5 (in Chinese).
23. Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, Hitman G, et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003 52 : 568 72.
24. Nielsen EM, Hansen L, Carstensen B, Echwald SM, Drivsholm T, Glumer C, et al. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 2003 52 : 573 7.
25. Riedel MJ, Steckley DC, Light PE. Current status of the E23K Kir6.2 polymorphism: implications for type-2 diabetes. Hum Genet 2005 116 : 133 45.
26. Schwanstecher C, Meyer U, Schwanstecher M. K(IR)6.2 polymorphism predisposes to type 2 diabetes by inducing overactivity of pancreatic beta-cell ATP-sensitive K(+) channels. Diabetes 2002 51 : 875 9.
27. Zychma MJ, Gumprecht J, Strojek K, Grzeszczak W, Moczulski D, Trautsolt W, et al. Sulfonylurea receptor gene 16-3 polymorphism-association with sulfonylurea or insulin treatment in type 2 diabetic subjects. Med Sci Monit 2002 8 : 512 5.
28. Hart LM, Dekker JM, van Haeften TW, Ruige JB, Stehouwer CD, Erkelens DW, et al. Reduced second phase insulin secretion in carriers of a sulphonylurea receptor gene variant associating with Type II diabetes mellitus. Diabetologia 2000 43 : 515 9.
29. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002 32 Suppl 3 : 14 23.
30. Rizzo MR, Barbieri M, Grella R, Passariello N, Paolisso G. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. Diabetes Metab 2005 31 (Pt 1) : 255 60.
31. Elbein SC, Sun J, Scroggin E, Teng, K, Hasstedt SJ. Role of common sequence variants in insulin secretion in familial type 2 diabetic kindreds: the sulfonylurea receptor, glucokinase, and hepatocyte nuclear factor 1alpha genes. Diabetes Care 2001 24 : 472 8.